Stocktoria
DYADIC INTERNATIONAL INC DYAI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2004-11-05
DYADIC INTERNATIONAL INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.1M | $3.5M | $2.9M | $2.9M | $2.4M |
| R&D expense | $2.2M | $2.0M | $3.3M | $4.5M | $8.4M |
| Operating income | -$7.2M | -$5.9M | -$8.2M | -$10.2M | -$14.7M |
| Income tax | — | — | — | — | $0 |
| Net income | -$7.4M | -$5.8M | -$6.8M | -$9.7M | -$13.1M |
| EPS (diluted) | $-0.23 | $-0.20 | — | — | — |
| Operating cash flow | -$5.7M | -$4.0M | -$6.7M | -$8.1M | -$11.3M |
| Cash & equivalents | $4.6M | $6.5M | $6.5M | $5.8M | $15.7M |
| Total assets | $9.9M | $9.9M | $8.2M | $13.7M | $21.3M |
| Total liabilities | $8.7M | $7.5M | $2.3M | $2.6M | $2.9M |
| Shareholders' equity | $1.2M | $2.5M | $5.9M | $11.1M | $18.4M |
Source: SEC EDGAR filings · CIK 0001213809 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.